US2014349397A1PendingUtilityA1
Reprogramming immortalized b cells
Est. expiryAug 4, 2030(~4.1 yrs left)· nominal 20-yr term from priority
C12N 2510/04C12N 2510/00C12N 2501/727C12N 15/63C12N 2501/603C12N 2501/605C12N 2501/604C12N 2506/11C12N 2501/15C12N 15/85C12N 2501/06C12N 2501/608C12N 2501/606C12N 2501/115C12N 2800/108C12N 5/0696C12N 2501/235C12N 2501/602C12N 2710/16243
55
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
Methods and composition for providing induced pluripotent stem (iPS) cells are provided. For example, in certain aspects methods including reprogramming B lymphocytes transformed by episomal vectors such as Epstein-Barr virus-based vectors are described. Furthermore, the invention provides induced pluripotent stem cells essentially free of exogenous elements and having B cell immunoglobin variable region rearrangement.
Claims
exact text as granted — not AI-modified1 .- 16 . (canceled)
17 . A human iPS cell having a genome that comprises an incomplete set of B cell immunoglobin variable region genes compared with an embryonic stem cell, wherein the iPS cell is essentially free of exogenous genetic elements.
18 . The human iPS cell of claim 17 , wherein the genome comprises a selected genetic marker.
19 . The human iPS cell of claim 18 , wherein the selected genetic marker is a genetic marker of a selected disease.
20 . The human iPS cell of claim 17 , wherein the genome is derived from an immortalized B cell.
21 . The human iPS cell of claim 20 , wherein the human iPS cell has a normal karyotype.
22 . A differentiated cell, tissue, or organ derived from the human iPS cell of claim 17 .Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.